Ozmosi | Rilvegostomig Drug Profile

Product Description

AZD-2936 is being developed by AstraZeneca for the treatment of solid tumors. (Sourced from: https://www.astrazeneca.com/our-therapy-areas/pipeline.html)

Mechanisms of Action: PD-1 Inhibitor, TIGIT Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rilvegostomig

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Moldova, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 82

Recent & Upcoming Milestones

Clinical Outcomes Expected - Compugen announced they will present P3 Biliary Tract Cancer results in 2H27 for Rilvegostomig
Clinical Outcomes Reported - AstraZeneca presented P2 Breast Cancer results on 2026-06-01 for Rilvegostomig
Clinical Outcomes Reported - AstraZeneca presented P1 Biliary Tract Cancer results on 2026-05-30 for Rilvegostomig

Highest Development Phases

Phase 1: Lymphoma|Sarcoma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04541108	PBI-MST-01	P1	Active, not recruiting	Lymphoma\|Melanoma\|Head and Neck Cancer\|Sarcoma\|Squamous Cell Carcinoma	2031-12-01	25%	2026-05-23
NCT07161414	ARTEMIDE-subQ	P1	Recruiting	Parkinson's Disease\|Lewy Body Disease	2027-07-19	30%	2025-12-25	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
jRCT2051250123	jRCT2051250123	P2	Recruiting	Non-Small-Cell Lung Cancer\|Small Cell Lung Cancer	2030-01-08
NCT07115043	D7350C00001	P2	Recruiting	Carcinoma, Merkel Cell\|Ovarian Cancer\|Non-Small-Cell Lung Cancer\|Melanoma\|Gastrointestinal Cancer\|Head and Neck Cancer\|Squamous Cell Carcinoma\|Skin Cancer\|Renal Cell Carcinoma\|Esophageal Cancer\|Triple Negative Breast Cancer	2029-10-02	55%	2026-08-20	Patient Enrollment\|Primary Endpoints\|Treatments
NCT06005493	D9750C00001	P2	Recruiting	Gastrointestinal Cancer\|Pancreatic Cancer\|Esophageal Cancer\|Pancreatic Ductal Carcinoma\|Adenocarcinoma	2029-03-16	44%	2026-09-26	Primary Completion Date\|Primary Endpoints
NCT03741426	WIRE	P2	Recruiting	Renal Cell Carcinoma	2027-12-30	37%	2026-09-26	Primary Endpoints
NCT05123482	BLUESTAR	P2	Recruiting	Endometrial Cancer\|Breast Cancer\|Non-Small-Cell Lung Cancer\|Ovarian Cancer\|Biliary Tract Cancer\|Squamous Cell Carcinoma	2027-09-29	42%	2025-12-11
NCT05414032	MERIDIAN	P2	Recruiting	Squamous Cell Carcinoma\|Head and Neck Cancer	2027-09-01	54%	2026-02-26	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date
NCT04379596	DG-03	P2	Active, not recruiting	Gastrointestinal Cancer\|Adenocarcinoma\|Esophageal Cancer	2027-05-04	53%	2026-08-29
2022-502317-29-00	D7987C00001	P2	Recruiting	Oncology Solid Tumor Unspecified	2026-11-25		2025-05-02	Treatments
NCT05775159	GEMINI-Hepatobiliary	P2	Active, not recruiting	Biliary Tract Cancer\|Hepatocellular Carcinoma	2026-10-27	57%	2026-07-03	Primary Endpoints\|Treatments\|Trial Status
2023-509436-26-00	D926UC00001	P2	Recruiting	Prostate Cancer\|Transitional Cell Carcinoma\|Ovarian Cancer\|Endometrial Cancer\|Biliary Tract Cancer\|Gastrointestinal Cancer\|Colorectal Cancer	2026-08-19	45%	2025-05-02	Treatments
2024-517780-24-00	D702GC00001	P3	Not yet recruiting	Lung Cancer	2031-01-25	94%
2023-506054-20-00	D7025C00001	P3	Recruiting	Gallbladder Cancer\|Biliary Tract Cancer\|Adenocarcinoma\|Muscle Cancer\|Cholangiocarcinoma	2030-09-30	94%	2025-05-02	Treatments
NCT07720284	TU-04	P3	Recruiting	Bladder Cancer\|Transitional Cell Carcinoma	2030-09-11	91%	2026-07-23	Primary Endpoints\|Treatments
NCT06109779	ARTEMIDE-Biliary01	P3	Active, not recruiting	Biliary Tract Cancer\|Skin Cancer\|Cholangiocarcinoma\|Bile Duct Cancer\|Gallbladder Cancer\|Klatskin Tumor	2029-01-02	94%	2026-07-11
NCT06564844	TROPION-Lung12	P3	Active, not recruiting	Non-Small-Cell Lung Cancer\|Adenocarcinoma	2026-07-10	93%	2026-09-24
jRCT2031250011	jRCT2031250011	P3	Recruiting	Esophageal Cancer\|Adenocarcinoma\|Gastrointestinal Cancer	2031-02-28
jRCT2061240062	jRCT2061240062	P3	Not yet recruiting	Non-Small-Cell Lung Cancer	2035-03-31
2024-512195-35-00	D926TC00001	P3	Not yet recruiting	Non-Small-Cell Lung Cancer\|Adenocarcinoma	2035-02-01	93%	2025-05-02	Treatments
jRCT2051250117	jRCT2051250117	P3	Recruiting	Small Cell Lung Cancer\|Non-Small-Cell Lung Cancer	2032-01-31
2024-519787-40-00	D9803C00001	P3	Not yet recruiting	Adenocarcinoma\|Gastrointestinal Cancer\|Esophageal Cancer	2031-10-27	80%
jRCT2031250781	jRCT2031250781	P3	Recruiting	Gastrointestinal Cancer\|Esophageal Cancer	2031-06-30
jRCT2011250015	jRCT2011250015	P3	Recruiting	Endometrial Cancer	2031-03-31
jRCT2041260098	jRCT2041260098	P3	Recruiting	Transitional Cell Carcinoma	2032-12-31

Recent News Events

Date	Type	Title
04/09/2026	News Article	Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
04/02/2026	News Article	IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
02/12/2026	News Article	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
12/17/2025	News Article	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Rilvegostomig

Alternative Names: Rilvegostomig, azd-2936, azd2936, azd 2936 Clinical Status: Active Latest Update: 2026-11-10 Latest Update Note: Clinical Trial Update